{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T21:09:21Z","timestamp":1773176961885,"version":"3.50.1"},"reference-count":76,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.clml.2019.09.620","type":"journal-article","created":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T11:35:40Z","timestamp":1570620940000},"page":"57-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Emerging Insights Into the Role of the Hippo Pathway in Multiple Myeloma and Associated Bone Disease"],"prefix":"10.1016","volume":"20","author":[{"given":"Anastasios","family":"Kyriazoglou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Ntanasis-Stathopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Despina","family":"Fotiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Gavriatopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"suppl 4","key":"10.1016\/j.clml.2019.09.620_bib1","doi-asserted-by":"crossref","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","article-title":"Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Moreau","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2019.09.620_bib2","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1038\/leu.2017.138","article-title":"Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study","volume":"31","author":"Kumar","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.09.620_bib3","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.09.620_bib4","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2019.09.620_bib5","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/14728214.2016.1186644","article-title":"Emerging antibodies for the treatment of multiple myeloma","volume":"21","author":"Zagouri","year":"2016","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.clml.2019.09.620_bib6","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1016\/j.clml.2019.03.008","article-title":"Multiple myeloma: clinical updates from the American Society of Hematology annual meeting, 2018","volume":"19","author":"Terpos","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2019.09.620_bib7","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/cncr.29771","article-title":"Impact of access to NCI- and NCCN-designated cancer centers on outcomes for multiple myeloma patients: a SEER registry analysis","volume":"122","author":"Ailawadhi","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2019.09.620_bib8","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1242\/dev.102376","article-title":"The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease","volume":"141","author":"Varelas","year":"2014","journal-title":"Development"},{"key":"10.1016\/j.clml.2019.09.620_bib9","doi-asserted-by":"crossref","first-page":"6555","DOI":"10.1021\/acs.biochem.5b01014","article-title":"YAP and TAZ take center stage in cancer","volume":"54","author":"Zhang","year":"2015","journal-title":"Biochemistry"},{"key":"10.1016\/j.clml.2019.09.620_bib10","doi-asserted-by":"crossref","first-page":"642","DOI":"10.15252\/embr.201438638","article-title":"The Hippo signaling pathway in stem cell biology and cancer","volume":"15","author":"Mo","year":"2014","journal-title":"EMBO Rep"},{"key":"10.1016\/j.clml.2019.09.620_bib11","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1158\/1541-7786.MCR-15-0305","article-title":"Control of proliferation and cancer growth by the Hippo signaling pathway","volume":"14","author":"Ehmer","year":"2016","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.clml.2019.09.620_bib12","doi-asserted-by":"crossref","first-page":"e1005465","DOI":"10.1371\/journal.pgen.1005465","article-title":"YAP1 exerts its transcriptional control via TEAD-mediated activation of enhancers","volume":"11","author":"Stein","year":"2015","journal-title":"PLoS Genet"},{"key":"10.1016\/j.clml.2019.09.620_bib13","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.cell.2012.06.037","article-title":"Regulation of the Hippo-YAP pathway by G-protein\u2013coupled receptor signaling","volume":"150","author":"Yu","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.clml.2019.09.620_bib14","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0076-6879(05)07025-4","article-title":"Nore1 and RASSF1 regulation of cell proliferation and of the MST1\/2 kinases","volume":"407","author":"Avruch","year":"2006","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.clml.2019.09.620_bib15","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.devcel.2009.12.012","article-title":"Kibra functions as a tumor suppressor protein that regulates Hippo signaling in conjunction with Merlin and Expanded","volume":"18","author":"Yu","year":"2010","journal-title":"Dev Cell"},{"key":"10.1016\/j.clml.2019.09.620_bib16","doi-asserted-by":"crossref","first-page":"357","DOI":"10.5483\/BMBRep.2016.49.7.104","article-title":"Merlin, a regulator of Hippo signaling, regulates Wnt\/beta-catenin signaling","volume":"49","author":"Kim","year":"2016","journal-title":"BMB Rep"},{"key":"10.1016\/j.clml.2019.09.620_bib17","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrm3416","article-title":"Transduction of mechanical and cytoskeletal cues by YAP and TAZ","volume":"13","author":"Halder","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.clml.2019.09.620_bib18","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cell.2014.05.035","article-title":"Cytoskeletal tension inhibits Hippo signaling through an Ajuba-Warts complex","volume":"158","author":"Rauskolb","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.clml.2019.09.620_bib19","first-page":"59","article-title":"Signaling in fibrosis: TGF-beta, Wnt, and YAP\/TAZ converge","volume":"2","author":"Piersma","year":"2015","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.clml.2019.09.620_bib20","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/ncb3216","article-title":"Genome-wide association between YAP\/TAZ\/TEAD and AP-1 at enhancers drives oncogenic growth","volume":"17","author":"Zanconato","year":"2015","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.clml.2019.09.620_bib21","doi-asserted-by":"crossref","first-page":"e1021441","DOI":"10.1080\/23723556.2015.1021441","article-title":"The Hippo effector YAP regulates the response of cancer cells to MAPK pathway inhibitors","volume":"3","author":"Lin","year":"2016","journal-title":"Mol Cell Oncol"},{"key":"10.1016\/j.clml.2019.09.620_bib22","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1073\/pnas.1216462110","article-title":"Regulation of Hippo pathway by mitogenic growth factors via phosphoinositide 3-kinase and phosphoinositide-dependent kinase-1","volume":"110","author":"Fan","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2019.09.620_bib23","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.celrep.2015.12.104","article-title":"Tead and AP1 coordinate transcription and motility","volume":"14","author":"Liu","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.clml.2019.09.620_bib24","doi-asserted-by":"crossref","first-page":"ra81","DOI":"10.1126\/scisignal.2004324","article-title":"Ajuba family proteins link JNK to Hippo signaling","volume":"6","author":"Sun","year":"2013","journal-title":"Sci Signal"},{"key":"10.1016\/j.clml.2019.09.620_bib25","doi-asserted-by":"crossref","first-page":"26245","DOI":"10.1074\/jbc.M112.382036","article-title":"The N-terminal phosphodegron targets TAZ\/WWTR1 protein for SCFbeta-TrCP\u2013dependent degradation in response to phosphatidylinositol 3-kinase inhibition","volume":"287","author":"Huang","year":"2012","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clml.2019.09.620_bib26","doi-asserted-by":"crossref","first-page":"119","DOI":"10.5483\/BMBRep.2018.51.3.018","article-title":"Clinical implications of the Hippo-YAP pathway in multiple cancer contexts","volume":"51","author":"Kim","year":"2018","journal-title":"BMB Rep"},{"key":"10.1016\/j.clml.2019.09.620_bib27","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1017\/erm.2015.12","article-title":"The Hippo transducers TAZ and YAP in breast cancer: oncogenic activities and clinical implications","volume":"17","author":"Maugeri-Sacca","year":"2015","journal-title":"Expert Rev Mol Med"},{"key":"10.1016\/j.clml.2019.09.620_bib28","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1158\/1078-0432.CCR-15-1447","article-title":"Inactivation of Hippo pathway is significantly associated with poor prognosis in hepatocellular carcinoma","volume":"22","author":"Sohn","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2019.09.620_bib29","doi-asserted-by":"crossref","first-page":"e65539","DOI":"10.1371\/journal.pone.0065539","article-title":"Overexpression of YAP and TAZ is an independent predictor of prognosis in colorectal cancer and related to the proliferation and metastasis of colon cancer cells","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2019.09.620_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10070229","article-title":"Epithelioid hemangioendothelioma as a model of YAP\/TAZ-driven cancer: insights from a rare fusion sarcoma","volume":"10","author":"Lamar","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2019.09.620_bib31","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1158\/0008-5472.CAN-10-2711","article-title":"Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF","volume":"71","author":"Lai","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2019.09.620_bib32","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1091\/mbc.E15-07-0456","article-title":"Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors","volume":"26","author":"Lin","year":"2015","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.clml.2019.09.620_bib33","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/gcc.20886","article-title":"A\u00a0novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites","volume":"50","author":"Errani","year":"2011","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.clml.2019.09.620_bib34","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/ng.3218","article-title":"The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies","volume":"47","author":"Lin","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.clml.2019.09.620_bib35","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/978-3-319-67577-0_14","article-title":"Adaptive resistance to cancer immunotherapy","volume":"1036","author":"McGray","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.clml.2019.09.620_bib36","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10555-011-9280-5","article-title":"Improving cancer immunotherapy by targeting tumor-induced immune suppression","volume":"30","author":"Stewart","year":"2011","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.clml.2019.09.620_bib37","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4049\/jimmunol.1101029","article-title":"Regulation of immune responses by prostaglandin E2","volume":"188","author":"Kalinski","year":"2012","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clml.2019.09.620_bib38","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nm.3541","article-title":"Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors","volume":"20","author":"Motz","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2019.09.620_bib39","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.bbrc.2017.07.007","article-title":"Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI\u2013resistant lung adenocarcinoma","volume":"491","author":"Lee","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.clml.2019.09.620_bib40","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1158\/2326-6066.CIR-17-0320","article-title":"YAP-induced PD-L1 expression drives immune evasion in BRAFi-resistant melanoma","volume":"6","author":"Kim","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.clml.2019.09.620_bib41","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1158\/0008-5472.CAN-17-3139","article-title":"The Hippo pathway component TAZ promotes immune evasion in human cancer through PD-L1","volume":"78","author":"Janse van Rensburg","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2019.09.620_bib42","doi-asserted-by":"crossref","first-page":"E114","DOI":"10.3390\/biomedicines6040114","article-title":"The role of yes-associated protein (YAP) in regulating programmed death-ligand 1 (PD-L1) in thoracic cancer","author":"Hsu","year":"2018","journal-title":"Biomedicines"},{"key":"10.1016\/j.clml.2019.09.620_bib43","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.tips.2013.08.006","article-title":"Regulation of the Hippo pathway and implications for anticancer drug development","volume":"34","author":"Park","year":"2013","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.clml.2019.09.620_bib44","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.phrs.2015.11.025","article-title":"Targeting the Hippo pathway: clinical implications and therapeutics","volume":"103","author":"Ye","year":"2016","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.clml.2019.09.620_bib45","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/bjc.2014.95","article-title":"Phase I\/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer","volume":"110","author":"Huggett","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clml.2019.09.620_bib46","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1002\/cncr.29502","article-title":"A\u00a0phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: a Wisconsin Oncology Network study","volume":"121","author":"Fenske","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2019.09.620_bib47","doi-asserted-by":"crossref","first-page":"e970055","DOI":"10.4161\/23723548.2014.970055","article-title":"Awakening the Hippo co-activator YAP1, a mercurial cancer gene, in hematologic cancers","volume":"1","author":"Cottini","year":"2014","journal-title":"Mol Cell Oncol"},{"key":"10.1016\/j.clml.2019.09.620_bib48","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1532\/IJH97.04107","article-title":"Apoptosis of multiple myeloma","volume":"80","author":"Oancea","year":"2004","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2019.09.620_bib49","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.leukres.2017.06.002","article-title":"Targeting autophagy in multiple myeloma","volume":"59","author":"Yun","year":"2017","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2019.09.620_bib50","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nm.3562","article-title":"Rescue of Hippo coactivator YAP1 triggers DNA damage\u2013induced apoptosis in hematological cancers","volume":"20","author":"Cottini","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2019.09.620_bib51","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nrc3876","article-title":"The emerging roles of YAP and TAZ in cancer","volume":"15","author":"Moroishi","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2019.09.620_bib52","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1158\/1541-7786.MCR-17-0382","article-title":"Novel YAP1 activator, identified by transcription-based functional screen, limits multiple myeloma growth","volume":"16","author":"Maruyama","year":"2018","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.clml.2019.09.620_bib53","first-page":"6880","article-title":"Sirtuin 6 promotes cell aging of myeloma cell line KM-HM (31) by via Hippo signal pathway","volume":"22","author":"Rui","year":"2018","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.clml.2019.09.620_bib54","first-page":"E37","article-title":"Circulating microRNAs and their role in multiple myeloma","volume":"5","author":"Federico","year":"2019","journal-title":"Noncoding RNA"},{"key":"10.1016\/j.clml.2019.09.620_bib55","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.cell.2013.12.043","article-title":"Hippo signaling regulates microprocessor and links cell-density\u2013dependent miRNA biogenesis to cancer","volume":"156","author":"Mori","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.clml.2019.09.620_bib56","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nrc3932","article-title":"MicroRNA biogenesis pathways in cancer","volume":"15","author":"Lin","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2019.09.620_bib57","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.18632\/oncotarget.6151","article-title":"Disentangling the microRNA regulatory milieu in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients","volume":"7","author":"Calura","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2019.09.620_bib58","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/path.5187","article-title":"Bone marrow fibroblasts overexpress miR-27b and miR-214 in step with multiple myeloma progression, dependent on tumour cell-derived exosomes","volume":"247","author":"Frassanito","year":"2019","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.clml.2019.09.620_bib59","doi-asserted-by":"crossref","first-page":"25127","DOI":"10.18632\/oncotarget.25350","article-title":"High expression of nucleoporin 133 mRNA in bone marrow CD138+ cells is a poor prognostic factor in multiple myeloma","volume":"9","author":"Ibata","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2019.09.620_bib60","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1182\/blood-2018-11-852459","article-title":"Myeloma bone disease: from biology findings to treatment approaches","volume":"133","author":"Terpos","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.09.620_bib61","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41408-017-0037-4","article-title":"Pathogenesis of bone disease in multiple myeloma: from bench to bedside","volume":"8","author":"Terpos","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2019.09.620_bib62","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/0008-5472.CAN-15-1703","article-title":"Bidirectional Notch signaling and osteocyte-derived factors in the bone marrow microenvironment promote tumor cell proliferation and bone destruction in multiple myeloma","volume":"76","author":"Delgado-Calle","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2019.09.620_bib63","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1038\/leu.2017.152","article-title":"Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth","volume":"31","author":"Delgado-Calle","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.09.620_bib64","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/leu.2011.381","article-title":"Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation","volume":"26","author":"Giuliani","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2019.09.620_bib65","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1146\/annurev.cellbio.20.010403.113126","article-title":"The Wnt signaling pathway in development and disease","volume":"20","author":"Logan","year":"2004","journal-title":"Annu Rev Cell Dev Biol"},{"key":"10.1016\/j.clml.2019.09.620_bib66","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13045-018-0615-3","article-title":"Wnt signaling in multiple myeloma: a central player in disease with therapeutic potential","volume":"11","author":"Spaan","year":"2018","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clml.2019.09.620_bib67","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41413-018-0018-7","article-title":"YAP promotes osteogenesis and suppresses adipogenic differentiation by regulating beta-catenin signaling","volume":"6","author":"Pan","year":"2018","journal-title":"Bone Res"},{"key":"10.1016\/j.clml.2019.09.620_bib68","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.cell.2015.07.013","article-title":"Alternative Wnt signaling activates YAP\/TAZ","volume":"162","author":"Park","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.clml.2019.09.620_bib69","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.devcel.2010.03.007","article-title":"The Hippo pathway regulates Wnt\/beta-catenin signaling","volume":"18","author":"Varelas","year":"2010","journal-title":"Dev Cell"},{"key":"10.1016\/j.clml.2019.09.620_bib70","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.celrep.2013.05.029","article-title":"SOX2 regulates YAP1 to maintain stemness and determine cell fate in the osteo-adipo lineage","volume":"3","author":"Seo","year":"2013","journal-title":"Cell Rep"},{"key":"10.1016\/j.clml.2019.09.620_bib71","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.biocel.2017.04.007","article-title":"YAP1 negatively regulates chondrocyte differentiation partly by activating the beta-catenin signaling pathway","volume":"87","author":"Yang","year":"2017","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.clml.2019.09.620_bib72","doi-asserted-by":"crossref","first-page":"e12453","DOI":"10.1111\/cpr.12453","article-title":"Fak-Mapk, Hippo and Wnt signalling pathway expression and regulation in distraction osteogenesis","volume":"51","author":"Song","year":"2018","journal-title":"Cell Prolif"},{"key":"10.1016\/j.clml.2019.09.620_bib73","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1002\/jcp.26372","article-title":"The emerging role of Hippo signaling pathway in regulating osteoclast formation","volume":"233","author":"Yang","year":"2018","journal-title":"J\u00a0Cell Physiol"},{"key":"10.1016\/j.clml.2019.09.620_bib74","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1089\/scd.2007.0074","article-title":"Elevated tumor necrosis factor-alpha suppresses TAZ expression and impairs osteogenic potential of Flk-1+ mesenchymal stem cells in patients with multiple myeloma","volume":"16","author":"Li","year":"2007","journal-title":"Stem Cells Dev"},{"key":"10.1016\/j.clml.2019.09.620_bib75","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1172\/JCI87802","article-title":"Reciprocal stabilization of ABL and TAZ regulates osteoblastogenesis through transcription factor RUNX2","volume":"126","author":"Matsumoto","year":"2016","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.clml.2019.09.620_bib76","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1600-0609.2010.01435.x","article-title":"The proteasome inhibitor bortezomib inhibits FGF-2\u2013induced reduction of TAZ levels in osteoblast-like cells","volume":"85","author":"Eda","year":"2010","journal-title":"Eur J Haematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019320075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265019320075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:34:38Z","timestamp":1761870878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265019320075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":76,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S2152265019320075"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.09.620","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging Insights Into the Role of the Hippo Pathway in Multiple Myeloma and Associated Bone Disease","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.09.620","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}